Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

New technology guides immune cells to fight brain cancer and multiple sclerosis

Researchers have found a way to program immune cells to attack glioblastoma and treat the inflammation of multiple sclerosis in mice.

6 Dec 2024

MRI-based imaging technique predicts the response of ovarian cancer to treatment

An MRI-based imaging technique developed at the University of Cambridge predicts the response of ovarian cancer tumors to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.

6 Dec 2024

New collaborative effort aims to cure ALK-positive lung cancer

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year.

6 Dec 2024

New immune therapy improves survival and reduces tumor burden in glioblastoma

The Wistar Institute's David B. Weiner, Ph.D. - Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research - and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma.

3 Dec 2024

New study unveils why glioblastoma becomes resistant to treatment

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the most aggressive forms of brain cancer, becomes resistant to treatment, and introduces a new approach that paves the way for more personalized treatment strategies for patients with this deadly brain tumor.

22 Nov 2024

Small brain-penetrating molecule offers hope for treating aggressive brain tumors

Gliocidin selectively kills glioblastoma cells by inhibiting nucleotide synthesis, showing potential as a therapeutic option in combination with temozolomide.

21 Nov 2024

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months.

19 Nov 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor environments, with promising clinical results.

13 Nov 2024

Breakthrough research reveals how to target malignant DNA in aggressive cancers

Scientists have discovered a way to target elusive circular fragments of DNA that drive the survival of some of the most aggressive cancers, paving the way for future treatments.

9 Nov 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

8 Nov 2024

Researchers awarded Synergy Grant to target tumor vessels and boost immunotherapy

Targeting and customizing blood vessels in tumors to increase T cell infiltration and maintain their function may represent the next breakthrough in cancer therapy.

5 Nov 2024

New targets identified for treating glioblastoma through genetic screen

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively treating glioblastoma, a lethal type of brain cancer.

4 Nov 2024

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

The 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened the world's top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy.

28 Oct 2024

Pioneering trial to test multiple new treatments for glioblastoma

A pioneering research study announced today (October 23) will trial multiple new treatments for people in the UK living with glioblastoma, an aggressive form of brain cancer.

26 Oct 2024

ALS drug shows promise in targeting glioblastoma stem cells

Glioblastoma is the most common – and the most malignant – primary brain tumor in adults. It's aggressive and incurable.

17 Oct 2024

Edaravone shows promise in targeting brain tumor stem cells

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy.

17 Oct 2024

New review explores Zika virus as a potential treatment for brain cancer

A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Zika virus and brain cancer: Can Zika be an effective treatment for brain cancer? A systematic review."

9 Oct 2024

Groundbreaking study challenges treatment protocols for glioblastoma in older adults

A groundbreaking study led by Dr Monika E. Hegi, MD, PhD and European Organisation for Research and Treatment of Cancer (EORTC) headquarters team (Felix Oppong Msc, Dr Thierry Gorlia, PhD) reveals that older adults glioblastoma patients with truly unmethylated MGMT promoter do not benefit from temozolomide (TMZ) treatment, challenging current treatment protocols and paving the way for more personalised therapies.

9 Oct 2024

Researchers discover effective treatment strategy for lethal glioblastoma

Glioblastoma (GBM) is the most lethal brain tumor, with a median survival rate of merely 12-16 months after diagnosis. Despite surgical, radiation and chemotherapy treatments, the two-year survival rate for GBM patients is less than 10%.

7 Oct 2024